Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus by Khan, Asif M et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Bioinformatics
Open Access Proceedings
Large-scale analysis of antigenic diversity of T-cell epitopes in 
dengue virus
Asif M Khan1,2, AT Heiny1,3, Kenneth X Lee1,2, KN Srinivasan1,4, 
Tin Wee Tan3, J Thomas August1,4 and Vladimir Brusic*2,5
Address: 1The Division of Biomedical Sciences, Johns Hopkins Singapore, 31 Biopolis Way, #02-01 The Nanos, Singapore 138669, Singapore, 
2Department of Microbiology, The Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117597, 
Singapore, 3Department of Biochemistry, The Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 
117597, Singapore, 4Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe 
Street, Baltimore, MD 21205, USA and 5School of Land and Food Sciences, and Institute for Molecular Biosciences, University of Queensland, 
Brisbane, QLD 4072, Australia
Email: Asif M Khan - g0501159@nus.edu.sg; AT Heiny - heiny@nus.edu.sg; Kenneth X Lee - leexunjian@gmail.com; 
KN Srinivasan - srinikn@jhmi.edu; Tin Wee Tan - bchtantw@nus.edu.sg; J Thomas August - taugust@bs.jhmi.edu; 
Vladimir Brusic* - v.brusic@uq.edu.au
* Corresponding author    
Abstract
Background: Antigenic diversity in dengue virus strains has been studied, but large-scale and detailed systematic
analyses have not been reported. In this study, we report a bioinformatics method for analyzing viral antigenic diversity
in the context of T-cell mediated immune responses. We applied this method to study the relationship between short-
peptide antigenic diversity and protein sequence diversity of dengue virus. We also studied the effects of sequence
determinants on viral antigenic diversity. Short peptides, principally 9-mers were studied because they represent the
predominant length of binding cores of T-cell epitopes, which are important for formulation of vaccines.
Results: Our analysis showed that the number of unique protein sequences required to represent complete antigenic
diversity of short peptides in dengue virus is significantly smaller than that required to represent complete protein
sequence diversity. Short-peptide antigenic diversity shows an asymptotic relationship to the number of unique protein
sequences, indicating that for large sequence sets (~200) the addition of new protein sequences has marginal effect to
increasing antigenic diversity. A near-linear relationship was observed between the extent of antigenic diversity and the
length of protein sequences, suggesting that, for the practical purpose of vaccine development, antigenic diversity of short
peptides from dengue virus can be represented by short regions of sequences (~<100 aa) within viral antigens that are
specific targets of immune responses (such as T-cell epitopes specific to particular human leukocyte antigen alleles).
Conclusion: This study provides evidence that there are limited numbers of antigenic combinations in protein sequence
variants of a viral species and that short regions of the viral protein are sufficient to capture antigenic diversity of T-cell
epitopes. The approach described herein has direct application to the analysis of other viruses, in particular those that
show high diversity and/or rapid evolution, such as influenza A virus and human immunodeficiency virus (HIV).
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Background
Dengue virus has four serotypes (DV1, DV2, DV3 and
DV4) that show substantial genetic diversity both within
and between serotypes. Sequence comparison studies
showed 30–40% difference in amino acid sequences
between serotypes [1,2]. The amino acid differences
within each serotype are lower but the observed intra-
serotype diversity is sufficiently large to warrant the defi-
nition of clusters of dengue virus variants [3,4]. Studies of
genetic diversity have focused on clade diversity and
replacement [4], mutation spectra [5], conserved regions
[6] and implications for clinical manifestations [3]. Sev-
eral studies have focused on the analysis of antigenic
diversity (diversity of targets of immune responses in pro-
tein sequences) of dengue virus; these studies focussed on
experimental mapping of antibody recognition sites [7-
11] and T-cell epitopes [2,12-15] and subsequent analysis
of their diversity. Recently, Simmons et al. [15] analyzed
the T cell responses of individuals infected with DV2 by
ELISpot assay and identified 34 peptides of several dengue
proteins as potential novel T-cell epitopes.
Generally, there is a correspondence between genetic and
antigenic evolution of viruses, but genetic changes may
result in disproportionately large antigenic changes
[16,17]. While genetic and antigenic diversity in dengue
virus strains had become evident [18], large-scale and
detailed systematic analyses that explore their relation-
ship have not been reported. Understanding this relation-
ship is important for the study of vaccine development,
especially in rapidly mutating viruses. In this paper, we
will focus on protein sequence diversity, and thus con-
sider only genetic variations that affect the protein
sequences.
Biological studies of antigenic diversity require great
experimental effort, even for a single viral protein. Conse-
quently, most research groups focus on studying small
number of viral sequences. Rapid accumulation of
sequence data from both classical and genomic/pro-
teomic approaches makes the experimental studying of
antigenic diversity difficult and time-consuming. A bioin-
formatics approach is necessary to support large-scale
antigenic analysis of viral diversity, which can comple-
ment laboratory experiments.
In this study, we have developed a bioinformatics method
to analyze antigenic diversity in the context of T-cell medi-
ated immune responses. We studied antigenic diversity of
more than 9000 dengue virus protein sequences reported
in the NCBI Entrez protein database [19]. The study
aimed to identify a minimal set of sequences that encodes
the complete antigenic diversity of short peptides from all
known sequences in dengue virus serotypes. Short pep-
tides, principally 9-mers were studied because they repre-
sent the predominant length of binding cores of T-cell
epitopes. We analysed the relationship between short-
peptide antigenic diversity and protein sequence diversity
of dengue virus; the analysis was performed at two time
points to help understand the effects of the accumulation
of sequence data to the relationship. We have also ana-
lyzed the effects of sequence determinants on antigenic
diversity of short peptides. This study provides a frame-
work for large-scale, systematic analysis of antigenic diver-
sity for the protein sequences of any virus. We did not
analyze B-cell epitope antigenic diversity because of their
complex conformational nature. Although linear B-cell
epitopes exist and our method can be used to study them,
very often, they also show conformational preferences
and dependence on the context of a protein antigen [20].
Further, only approximately 10% of B-cell epitopes from
native proteins are linear [21].
Results
Dengue serotype protein datasets
Data of June 2004 (Table 1), collected from the NCBI Ent-
rez protein database, contained a total of 3699 sequences
representing the ten proteins encoded by the genomes of
the four serotypes (Table 2). The number of these reported
sequences increased nearly three-fold during the follow-
ing 18 months (9512 sequences; see Table 1). The
removal of duplicates (identical protein sequences)
reduced these collected sequences to 1318 (2004) and
2419 (2005) unique sequences (Table 1). More than 64%
of the sequences collected in 2004 were identical and
redundant, and this redundancy increased by approxi-
mately 10% in 2005 (75%). The number of reported
unique sequences varied greatly among the proteins, rang-
ing from 69 NS4a to 998 E sequences in 2005 set (Table
3). Minor errors of annotation, mainly of the cleavage
sites, were corrected prior to analysis for 17 sequences (see
additional file 1: Table S1.pdf).
Intra- and inter-serotype amino acid sequence identities of 
dengue proteins
Earlier studies of dengue proteins, mainly E and NS1
[1,22-25], have shown substantial amino acid sequence
diversity both within and between the serotypes. In our
study, we surveyed the extent of amino acid variation and
conservation among dengue viruses by calculating pair-
wise percentage amino acid identity of unique sequences
for each dengue protein, intra- and inter-serotype, using
the large dengue data set of 2005. The intra- and inter-
serotype percentage sequence identities (PSI) for all den-
gue proteins are shown in Table 4.
The intra-serotype percentage sequence identity was
between 92% and 99%, except for C, pM, E and NS1 of
DV2, which showed minimum sequence identities rang-
ing from 79% to 89%. In contrast, the average inter-sero-BMC Bioinformatics 2006, 7(Suppl 5):S4
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type percentage sequence identity was in the range of 60–
79%, except for NS2a. The NS3, NS4b and NS5 proteins
are highly conserved across the serotypes, with average
sequence identities in the range of 77–79%, probably
because of their involvement in forming the RNA replica-
tion complex [26]. The NS2a protein is the most diverse
across the serotypes (average PSI of 39%), although it is
highly conserved within each serotype. The inter-serotype
diversity observed for NS2a is comparable to the inter-Fla-
vivirus  diversity of the envelope protein, which shows
approximately 40% amino acid identity [27].
Minimal sequence sets representing dengue virus antigenic 
diversity
In addition to identical protein sequences, another source
of sequence redundancy, relative to this study, is the pres-
ence of antigenically redundant sequences. These
sequences exist because of the identity of many amino
acid residues among the individually unique protein
sequences (see Results section sub-heading: Intra- and
inter-serotype amino acid sequence identities of dengue pro-
teins), resulting in the presence of targets of T-cell medi-
ated immune responses (T-cell epitopes) that are identical
among viral variants. Antigenically redundant sequences
can be removed without loss of information on antigenic
diversity among the sequences sets. For example, if in a
dataset of three sequences, all of the overlapping 9-mers
in one sequence have a match in at least one of the other
two sequences, the antigenic diversity of this sequence can
be covered by the other two sequences combined, thus
rendering the first sequence antigenically redundant (Fig-
ure 1).
The removal of antigenically redundant sequences using
our bioinformatics method (see Methods section sub-
heading: Protein sequence and antigenic diversity analysis of
dengue virus) resulted in a further reduction of the number
of dengue unique sequences to a total of 969 (2004 set) or
1684 (2005 set). Those two sets represent the complete
antigenic diversity of short peptides for all four dengue
serotypes (Table 5). The increase in the number of unique
sequences required to represent the complete antigenic
diversity of short peptides in the four dengue serotypes in
2005 (compared to 2004) is an indication that more
short-peptide antigenic diversity was found in the new
sequences accumulated in the database. However, the per-
centage of unique sequences required to represent the
complete short-peptide antigenic diversity of all four den-
gue serotypes in 2005 decreased (from 74% in 2004 to
70% in 2005) because of an increase in antigenic redun-
dancy. This observation indicates that the increase in the
number of unique protein sequences (representing pro-
Table 2: Proteins of a representative dengue virus serotype 2 polyprotein entry (P14340 of 3391 amino acids) in the NCBI Entrez 
protein database.
Protein Length (amino acids)
Capsid (C) 114
Precursor membrane (pM) 166
Envelope (E) 495
Nonstructural protein 1 (NS1) 352
Nonstructural protein 2a (NS2a) 218
Nonstructural protein 2b (NS2b) 130
Nonstructural protein 3 (NS3) 618
Nonstructural protein 4a (NS4a) 150
Nonstructural protein 4b (NS4b) 248
Nonstructural protein 5 (NS5) 900
Table 1: Collected and unique protein sequences for each dengue serotype in 2004 and 2005 and the corresponding increase in data 
between the two time points.
Dengue serotype Data retrieved in 2004 (#) Data retrieved in 2005 (#) Increase (#)
Collected 
sequences
Unique sequences Collected 
sequences
Unique sequences Collected 
sequences
Unique sequences
DV1 744 359 2318 724 1574 365
DV2 1426 507 3351 697 1925 190
DV3 597 230 2520 678 1923 448
DV4 932 222 1323 320 391 98
T o t a l3 6 9 91 3 1 89 5 1 22 4 1 95 8 1 31 1 0 1BMC Bioinformatics 2006, 7(Suppl 5):S4
Page 4 of 12
(page number not for citation purposes)
tein sequence diversity) deposited in public databases is
generally accompanied by a slower increase in short-pep-
tide antigenic diversity.
Characterization and application of sequence variables 
that affect antigenic diversity
We examined the effects of sequence determinants, such
as number and length of sequences, on the short-peptide
antigenic diversity of dengue virus. These analyses were
carried out using test datasets of different numbers of
sequences (20, 40, 60, 80, 100, 120 and 140 sequences)
and different lengths (23, 46, 128, 138, 276 and 460 aa)
that were randomly selected from a set of DV2 envelope
protein sequences with repeated sampling for 20 times.
Antigenic diversity analysis of each test dataset was per-
formed to identify a minimal set of sequences that repre-
sents the complete short-peptide antigenic diversity for
each dataset. These minimal sets were used to analyze the
Table 4: Minimum and maximum percentage sequence identity range for each dengue protein, intra- and inter-serotype.
DV1 DV2 DV3 DV4 Average PSI DV1 DV2 DV3 DV4 Average PSI
C DV1 88–99 65 pM DV1 92–99 68
DV2 56–75 81–99 DV2 62–75 79–99
DV3 75–84 53–66 91–99 DV3 75–82 60–72 93–99
DV4 61–68 57–69 54–60 94–99 DV4 62–67 60–71 64–70 96–99
E DV1 89–99 65 NS1 DV1 93–99 72
DV2 58–70 80–99 DV2 68–75 85–99
DV3 72–79 60–69 92–99 DV3 77–80 69–75 94–99
DV4 58–66 55–65 61–64 94–99 DV4 67–70 68–73 70–74 93–99
NS2a DV1 90–99 39 NS2b DV1 93–99 60
DV2 36–40 93–99 DV2 56–62 95–99
DV3 43–48 35–40 93–99 DV3 66–70 58–63 96–99
DV4 35–39 33–36 36–41 89–99 DV4 56–62 54–59 56–59 94–99
NS3 DV1 97–99 79 NS4a DV1 92–99 60
DV2 78–80 96–99 DV2 56–61 96–99
DV3 84–86 79–81 97–99 DV3 63–68 56–63 92–99
DV4 75–77 75–77 77–79 97–99 DV4 56–60 59–64 56–62 94–99
NS4b DV1 95–99 78 NS5 DV1 96–99 77
DV2 75–79 95–99 DV2 77–79 95–99
DV3 81–85 75–79 97–99 DV3 80–82 77–79 96–99
DV4 75–78 77–81 76–79 97–99 DV4 73–76 72–75 74–77 95–99
The average percentage sequence identities (PSI) are shown for inter-serotype comparisons.
Table 3: Unique sequences for the proteins of the four serotypes in 2004 and 2005.
Protein No. of unique sequences (all four serotypes)
2004 2005
C1 0 7 1 9 6
pM 126 220
E4 9 5 9 9 8
NS1 150 224
NS2a 95 142
NS2b 59 78
NS3 80 164
NS4a 37 69
NS4b 57 88
NS5 112 240
Total 1318 2419BMC Bioinformatics 2006, 7(Suppl 5):S4
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effects of the sequence determinants on antigenic diver-
sity.
Effects of number of sequences on short-peptide antigenic diversity
An increase in the number of unique sequences in a data-
set reduces the fraction required to represent the complete
short-peptide antigenic diversity (Table 6). This observa-
tion reflects an asymptotic relationship between the
number of unique sequences and the percentage of the
complete short-peptide antigenic diversity that is covered
(Figure 2). Asymptotic curves were observed for all pro-
teins of the four dengue serotypes (data not shown). The
shape of the curve indicates that a single sequence will
cover only a small proportion of the total short-peptide
antigenic diversity and that for proteins with a large
number of unique sequences, the addition of a single new
Definition of antigenically redundant sequence Figure 1
Definition of antigenically redundant sequence. A) The three sequences (NCBI GI no.: 1854039, 17129648 and 
37963458) are each unique, and residues that vary among them are shown. B) Overlapping 9-mers generated from the three 
unique sequences represent all the inherent antigenic variations, with respect to potential 9-mer T-cell epitopes. Although the 
three sequences are each unique, they share identical 9-mers. 9-mers shown in uppercase are those with an identical match in 
two of the unique sequences analyzed, while those in bold uppercase have an identical match in all three sequences; unique 9-
mers are shown in lowercase. All the 9-mers in sequence 1854039 have a match in at least one of the other two sequences; 
thus, the antigenic diversity of this sequence can be covered by the other two sequences combined, rendering the sequence 
1854039 antigenically redundant. Hence, the minimal number of sequences required to represent antigenic diversity for this 
dataset is two.
A) Three unique sequences from the NCBI Entrez protein database. 
1854039 ASIILEFFLMVLLIPEPDRQRT 
17129648 ASIILEFFLMVLLIPEPDRLRT 
37963458 ASIILEFLLMVLLIPEPDRQRT 
  ******* *********** ** 
Consensus ASIILEFFLMVLLIPEPDRQRT 
Variable residues         L           L   
B) Overlapping 9-mers generated from the three unique sequences represent 
all the inherent antigenic variations, with respect to potential 9-mer T-
cell epitopes. 
>37963458 >1854039  >17129648 
ASIILEFLLMVLLIPEPDRQRT ASIILEFFLMVLLIPEPDRQRT ASIILEFFLMVLLIPEPDRLRT 
asiilefll ASIILEFFL ASIILEFFL 
 siilefllm   SIILEFFLM   SIILEFFLM 
  iilefllmv    IILEFFLMV    IILEFFLMV 
   ilefllmvl     ILEFFLMVL     ILEFFLMVL 
    lefllmvll      LEFFLMVLL      LEFFLMVLL 
     efllmvlli       EFFLMVLLI       EFFLMVLLI 
      fllmvllip        FFLMVLLIP        FFLMVLLIP 
       llmvllipe         FLMVLLIPE         FLMVLLIPE 
        LMVLLIPEP          LMVLLIPEP          LMVLLIPEP 
         MVLLIPEPD           MVLLIPEPD           MVLLIPEPD 
          VLLIPEPDR            VLLIPEPDR            VLLIPEPDR 
           LLIPEPDRQ             LLIPEPDRQ             llipepdrl 
            LIPEPDRQR              LIPEPDRQR              lipepdrlr 
             IPEPDRQRT               IPEPDRQRT               ipepdrlrt BMC Bioinformatics 2006, 7(Suppl 5):S4
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variant sequence has little effect on the overall antigenic
diversity.
Effects of length of sequences on short-peptide antigenic diversity
A decrease in the length of sequences of a dataset reduces
the fraction required to represent the complete short-pep-
tide antigenic diversity of the dataset (Table 7). This
reduction was achieved by removal of two types of redun-
dancy: identical fragments and antigenically redundant
fragments. The number of identical fragments increases
significantly with a decrease in the length of the fragments
because of the limited variability associated with smaller
size. Hence, the effect of sequence length is significant,
especially for very short fragments (23 aa), for which only
~7% of the unique fragments were required to represent
complete antigenic diversity of the short fragments (a
reduction of ~93%). Overall, the results indicate that
short-peptide antigenic diversity has a near-linear rela-
tionship to sequence length (Figure 3).
Discussion
In this study, we applied a systematic bioinformatics
approach to collect, clean, organize and analyze the anti-
genic diversity of short peptides in reported protein
sequence data of dengue virus. We have developed a com-
putational method for the analysis of antigenic diversity
in the context of T-cell mediated immune responses. The
method was applied for the analysis of short-peptide anti-
genic diversity of dengue virus to determine a minimal
sequence set that encodes the complete antigenic diversity
of linear epitopes within each dengue virus serotype. We
studied the relationship between short-peptide antigenic
diversity and protein sequence diversity of DV and also
explored the effects of sequence determinants on viral
antigenic diversity. Our analysis showed that the minimal
number of unique sequences required to represent com-
plete antigenic diversity of linear epitopes in dengue virus
is significantly smaller than that required to represent
complete protein sequence diversity. Short-peptide anti-
genic diversity shows an asymptotic relationship to the
number of unique sequences and linear relationship to
the length of protein antigens.
The minimal sequence set that encodes the complete
short-peptide antigenic diversity for each dengue virus
serotype was derived through removal of identical
sequences and antigenically redundant sequences (Table
5 and Figure 4). Both reductions occurred without any
loss of information on antigenic diversity among the
sequences. The largest reduction was accomplished
through the removal of identical sequences, since only
36% (year 2004) or 25% (year 2005) of the sequences
Table 6: Effects of number of unique dengue virus serotype 2 (DV2) envelope sequences (N) on short-peptide (9-mer) antigenic 
diversity.
Number of unique sequences (N) 20 40 60 80 100 120 140
Length of sequences 460 aa 460 aa 460 aa 460 aa 460 aa 460 aa 460 aa
Minimal number of unique sequences that represent complete short-peptide antigenic 
diversity (Mean ± SE)
18 ± 0.30 32 ± 0.54 46 ± 0.70 58 ± 0.87 70 ± 0.87 80 ± 0.87 90 ± 0.71
Percentage of unique sequences that represent complete short-peptide antigenic 
diversity (%) (Mean ± SE)
90 ± 1.5 80 ± 1.35 77 ± 1.17 73 ± 1.09 70 ± 0.87 67 ± 0.73 64 ± 0.51
The mean and standard error (SE) values are shown for random repeated sampling of 20 times.
Table 5: Reduction of the number of unique dengue sequences by removal of antigenically redundant sequences.
Dengue serotype Data retrieved in 2004 Data retrieved in 2005
Unique sequences 
(#)
Minimal antigenic set Unique sequences 
(#)
Minimal antigenic set
Unique sequences 
(#)*
Percentage of 
unique sequences 
(%)**
Unique sequences 
(#)*
Percentage of 
unique sequences 
(%)**
DV1 359 244 68% 724 493 68%
DV2 507 368 73% 697 466 67%
DV3 230 180 78% 678 482 71%
DV4 222 177 80% 320 243 76%
Total 1318 969 74% 2419 1684 70%
*Minimal no. of unique sequences that represent complete short-peptide (9-mer) antigenic diversity of dengue unique sequences reported in NCBI 
Entrez protein database. **Percentage of unique sequences that represent complete short-peptide (9-mer) antigenic diversity of dengue unique 
sequences reported in the NCBI Entrez protein database.BMC Bioinformatics 2006, 7(Suppl 5):S4
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were unique. The identical sequences originated from
dengue virus strains that were unique variants with respect
to the whole polyprotein, but were identical to other den-
gue strains with respect to individual proteins, resulting in
many duplicate protein sequences. The removal of anti-
genically redundant sequences also involved a significant
proportion of the sequences, approximately one-third of
all unique sequences (2004: 26%; 2005: 30%), reflecting
the high antigenic redundancy among the dengue virus
variants, which often differed by only a few amino acids.
Despite significant reduction achieved by reducing the
collected sequences to minimal sequences, a large number
of protein sequences, 969 in 2004 and 1684 in 2005, were
still required to represent the complete short-peptide anti-
genic diversity of dengue virus.
It is clear that antigenic diversity in the reported dengue
sequences is large. With many asymptomatic human and
animal carriers of dengue viruses representing a huge res-
ervoir for emergence of new strains [6,24,28], the diversity
is expected to increase, although at a progressively slower
pace. This is because antigenic redundancy increases when
Table 7: Effect of length of dengue virus serotype 2 (DV2) envelope protein sequences on short-peptide (9-mer) antigenic diversity.
Length of fragments 100% (460 aa) 60% (276 aa) 30% (138 aa) 20% (92 aa) 10% (46 aa) 5% (23 aa)
Number of fragments 187 187 187 187 187 187
Number of unique fragments 187 131 82 58 27 17
Minimal number of fragments that represent complete 
short-peptide antigenic diversity (Mean ± SE)
111 ± 0.11 74 ± 0.11 48 ± 0.17 38 ± 0.10 24 ± 0.10 14 ± 0.10
Percentage of fragments that represent complete short-
peptide antigenic diversity (%) (Mean ± SE)
59 ± 0.06 40 ± 0.06 26 ± 0.09 20 ± 0.05 13 ± 0.05 7 ± 0.05
The mean and standard error (SE) values are shown for random repeated sampling of 20 times.
Short-peptide (9-mer) antigenic diversity as a function of number of sequences Figure 2
Short-peptide (9-mer) antigenic diversity as a function of number of sequences. Short-peptide antigenic diversity 
has an asymptotic relationship to number of unique dengue virus serotype 2 (DV2) envelope sequences (N). Each curve shows 
the cumulative percentage coverage of short-peptide antigenic diversity. Vertical bars represent standard error for repeated 
random sampling of 20 times.
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the number of sequences increases; we observed that
when the dataset for a particular protein reaches approxi-
mately 200 sequences, the effect of addition of new
sequences to increasing antigenic diversity is marginal.
Our study of factors that affect antigenic diversity pro-
vided insight into dealing with the increasing T-cell
epitope antigenic diversity in the context of vaccine devel-
opment. Length of sequences had the largest effect on
short-peptide antigenic diversity. The asymptotic behav-
iour of antigenic diversity increase was observed for the
increase in the number of sequence variants. For practical
purposes of vaccine formulation, antigenic diversity can-
not be represented by whole protein sequences because it
is not feasible to use these sequences for systematic exper-
imental analysis: they are long and their number is
increasing rapidly. The implication is that conventional
vaccination strategies, which utilize whole attenuated
pathogen with little knowledge of the specificity of
immune responses they elicit, may not be suitable for pro-
viding protection from multiple variants of viruses. Fur-
thermore, it may be difficult to optimize such vaccine
according to the human leukocyte antigen (HLA) profile
of the population receiving the vaccine [29,30], as neither
the identities of the HLA molecules that bind T-cell
epitopes, nor the epitopes themselves are known.
The more effective vaccine strategy that we propose is to
focus on short segments of proteins (~<100 aa) that are
known to be specific targets of immune responses (such as
T-cell epitopes specific to particular HLA alleles), particu-
larly those that have high concentration of T-cell epitopes
[31]. By combining selected sets of short antigen frag-
ments that represent T-cell epitope antigenic diversity,
complete sets of viral targets can be covered in a "divide-
and-conquer" approach. This may provide a promising
basis for multivalent peptide-based vaccines against den-
gue virus. However, this strategy does not address the den-
gue virus-specific problem of protection versus
immunopathology during secondary infections with a dif-
ferent serotype [2].
Several caveats need to be considered in a study such as
this. First, it is well-known that not all HLA-restricted
Short-peptide (9-mer) antigenic diversity as a function of length of sequences Figure 3
Short-peptide (9-mer) antigenic diversity as a function of length of sequences. Short-peptide antigenic diversity 
shows a linear relationship to the sequence length of dengue virus serotype 2 (DV2) envelope protein. Vertical bars represent 
standard error for repeated random sampling of 20 times.
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epitopes are 9-mers [32]. This may impact the interpreta-
tion of our results, which were based only on 9-mers, and
hence may not give a true representation of dengue T-cell
epitope antigenic diversity. We selected 9-mers because
they represent the typical size of HLA class I T-cell
epitopes, as well as the binding core of HLA class II T-cell
epitopes [32]. We performed the same analysis with pep-
tides of 8-mers and 10-mers. The results showed no signif-
icant difference as compared to the analysis of 9-mers
(data not shown).
The second caveat is the sampling bias in dengue virus
sequences reported to the public databases. Only dengue
sequences that have been studied are reported, and viruses
collected in accessible locations, associated with notable
disease outbreaks or of known immunological properties
are preferentially studied. Consequently, certain dengue
proteins have been studied intensively, while the others
remained largely unstudied. For example, sequences of
the envelope protein, known to be important for immu-
nological activity and viral entry into host [26,33], were
the most abundant in our dataset (3183 sequences for all
four serotypes), while that of NS4a, which is relatively
unknown for immunological activity, was under-repre-
sented. In addition, for majority of the proteins, a large
portion of the reported sequences were incomplete in
length. For example, 95% of DV2 NS5 collected sequences
were incomplete in length (data not shown). However,
the data used in this study was the most representative
available and the large sample size for majority of the pro-
teins helps to decrease the margin of error due to sam-
pling bias. In addition, the reported sequences represent
highly pathogenic strains isolated during dengue out-
breaks.
There has been no significant increase in the number of
unique sequences for dengue virus since the last analysis
(December 2005). The September 2006 data set con-
tained a total of 2661 (793 DV1, 784 DV2, 759 DV3 and
325 DV4) dengue unique sequences. This was an increase
of 242 unique sequences from the 2005 data set. The
increase, approximately 10%, was not expected to signifi-
cantly affect the results observed for 2005 data set. There-
fore, we did not perform the analysis of antigenic diversity
on the 2006 data set because of the small increase in the
number of unique sequence.
Conclusion
This study has provided evidence that there are limited
numbers of antigenic combinations in variant protein
sequences of a viral species and that short regions of the
viral proteins are sufficient to capture antigenic diversity
of T-cell epitopes. The approach described herein has
direct application to the analysis of other viruses, in par-
Flowchart summarizing the steps undertaken to identify the antigenically relevant unique sequence for dengue virus Figure 4
Flowchart summarizing the steps undertaken to identify the antigenically relevant unique sequence for dengue virus.
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ticular those that show high diversity and/or rapid evolu-
tion, such as influenza A virus and human
immunodeficiency virus (HIV).
Methods
Data collection
All dengue virus protein sequence entries present in the
NCBI Entrez protein database [34] were collected in June
2004 and then again in December 2005. Data retrieval
was performed through the NCBI taxonomy browser [19]
and the respective taxonomy ID for each of the dengue
serotypes (DV1-4) are 11053, 11060, 11069 and 11070.
The collected entries for both time points were processed
separately using identical procedures.
Data processing: cleaning and grouping
The dengue virus RNA genome is translated into a single
polyprotein (~3390 aa) that is cleaved by proteases to
yield 10 dengue proteins: the C protein; the M protein,
which is synthesized as a larger precursor protein pM; the
major E glycoprotein; and seven nonstructural (NS) pro-
teins, NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 (Table
2). Individual protein sequences were extracted from col-
lected entries for each DV serotype and grouped according
to the 10 dengue proteins for analysis. The protein
sequence extraction was done by sequence alignments
and identification of known cleavage sites for dengue pro-
teins. The cleavage sites were obtained from the annota-
tion of the GenPept [19] reference polyprotein sequence
for each dengue serotype (DV1: AAF59976; DV2: P14340;
DV3: AAM51537; DV4: AAG45437) and the literature
[35]. The grouping of the extracted sequences for proteins
of each serotype was facilitated by local sequence align-
ment using the BLAST algorithm [36] (parameters: filter –
no; expect – 100; descriptions & alignments – 1000), fol-
lowed by multiple sequence alignment using ClustalX
1.83 [37] with default parameters, followed by manual
inspection. Duplicate or identical sequences for proteins
within each serotype were removed, and the unique
sequences were retained for further analysis. Both full-
length and partial unique sequences of each dengue sero-
type protein were used for the analysis, unless indicated
otherwise. Data compiled from public databases are
prone to errors and discrepancies [38], which may affect
the analysis. Therefore, we inspected the collected DV
entries and corrected errors and discrepancies (see addi-
tional file 1: Table S1.pdf).
Protein sequence and antigenic diversity analysis of 
dengue virus
In the context of this study, protein sequence diversity of
a dengue protein was defined as the total number of
unique sequences reported in the database for the protein.
Sequences having at least a single amino acid difference
between them were considered as unique. We calculated
the pairwise percentage amino acid identity of the full-
length unique sequences of each dengue protein, intra-
and inter-serotype, by use of ClustalW 1.83 [39] with
default parameters, followed by manual inspection. This
was done to survey the extent of amino acid variation and
conservation in the latest, comprehensive dengue data of
2005.
Antigenic diversity of a dengue protein was defined in this
study as the minimal set of unique sequences required to
represent the complete set of overlapping 9-mer peptides
encoded by all unique sequences reported in the database
for the protein. We developed a bioinformatics method
that performs exhaustive search to determine the minimal
set for a given protein. The method comprises two steps:
(a) generation of a set of overlapping 9-mers from the
entire length of all unique sequences reported in the data-
base for the protein, followed by (b) identification of a
minimal set of unique sequences that represents all the
unique 9-mers. The union of such sets for all the ten pro-
teins of a dengue serotype represents the antigenic diver-
sity of the proteins for the serotype as defined in this
study. The computer program for the method was written
in Perl and C language.
In the first step of the method, we generated overlapping
9-mers from the entire length of each unique sequence
because the whole length was assumed to contain poten-
tial targets of T-cell mediated immune responses (T-cell
epitopes) [40]. This assumption was based, firstly, on the
estimate that from a complete set of overlapping peptides
(9 or 10-mers) spanning a protein, on average, 0.1–5% of
the peptides will bind to any particular HLA molecule
[41]. Secondly, given the large number of HLA molecules
(more than 2532 known as of September 2006; [42]), the
vast majority of the complete set of overlapping peptides
are highly likely to bind at least one molecule from the
total HLA pool. Thus, each overlapping peptide is a poten-
tial T-cell epitope. This assumption ensures the capture of
all possible candidate 9-mer T-cell epitopes that can be
present across the entire length of the unique sequence.
We focused our antigenic diversity study on 9-mers
because they represent the predominant length of HLA
class I T-cell epitopes, as well as the binding core of HLA
class II T-cell epitopes [32,40]. Furthermore, our prelimi-
nary analysis using 8-mers and 10-mers did not produce
notably different results compared to the analysis of 9-
mers (data not shown). A small number of 9-mers derived
from the unique sequences contained unknown residues
(denoted by "X") and, hence, were excluded from the
analysis because they were antigenically non-informative.BMC Bioinformatics 2006, 7(Suppl 5):S4
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Determining the effects of sequence determinants on 
antigenic diversity
The effects on antigenic diversity of two sequence determi-
nants, the number of viral sequences in the studied set
and the length of protein antigens were studied. The study
was performed on unique sequences from the DV2 enve-
lope protein (retrieved in 2005) because it provided a suf-
ficiently large and well-defined dataset (198 full-length
sequences). Test datasets with different numbers of
sequences (20, 40, 60, 80, 100, 120 and 140 sequences)
and different lengths (23, 46, 128, 138, 276 and 460 aa)
were randomly derived from the envelope dataset with
repeated sampling (20 repeats). Any duplicate sequences
were removed from the test datasets. The minimal set of
sequences that represents the complete short-peptide anti-
genic diversity was determined for each dataset. These
minimal sets were used to analyze the effects of the
sequence determinants on antigenic diversity.
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